1.Kang, CI, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clinical Infectious Diseases 2003; 37: 745–751.
2.Lodise, TP Jr., et al. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrobial Agents and Chemotherapy 2007; 51: 3510–3515.
3.Osih, RB, et al. Impact of empiric antibiotic therapy on outcomes in patients with Pseudomonas aeruginosa bacteremia. Antimicrobial Agents and Chemotherapy 2007; 51: 839–844.
4.Wisplinghoff, H, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clinical Infectious Diseases 2004; 39: 309–317.
5.Giske, CG, et al. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrobial Agents and Chemotherapy 2008; 52: 813–821.
6.Falagas, ME, Kopterides, P. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. Journal of Hospital Infection 2006; 64: 7–15.
7.Schechner, V, et al. Gram-negative bacteremia upon hospital admission: when should Pseudomonas aeruginosa be suspected? Clinical Infectious Diseases 2009; 48: 580–586.
8.Aloush, V, et al. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrobial Agents and Chemotherapy 2006; 50: 43–48.
9.Tam, VH, et al. Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 2010; 54: 1160–1164.
10.Defez, C, et al. Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection. Journal of Hospital Infection 2004; 57: 209–216.
11.Falagas, ME, et al. Risk factors for isolation of strains susceptible only to polymyxin among patients with Pseudomonas aeruginosa bacteremia. Antimicrobial Agents and Chemotherapy 2006; 50: 2541–2543.
12.Russell, JA. Management of sepsis. New England Journal of Medicine 2006; 355: 1699–1713.
13.Charlson, ME, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases 1987; 40: 373–383.
14.Knaus, WA, et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991; 100: 1619–1636.
15.Harris, AD, et al. Methodological principles of case–control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clinical Infectious Diseases 2001; 32: 1055–1061.
16.Tumbarello, M, et al. Bloodstream infections caused by extended-spectrum-b-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrobial Agents and Chemotherapy 2006; 50: 498–504.
17.Garner, JS, et al. CDC definitions for nosocomial infections, 1988. American Journal of Infection Control 1988; 16: 128–140.
18.Friedman, ND, et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Annals of Internal Medicine 2002; 137: 791–797.
19.Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 17th Informational Supplement. Document M100-S17. Wayne, PA: CLSI, 2007.
20.Marchaim, D, et al. Epidemiology of bacteremia episodes in a single center: increase in Gram-negative isolates, antibiotics resistance, and patient age. European Journal of Clinical Microbiology & Infectious Diseases 2008; 27: 1045–1051.
21.Carmeli, Y, et al. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrobial Agents and Chemotherapy 1999; 43: 1379–1382.
22.Gasink, LB, et al. Risk factors for and impact of infection or colonization with aztreonam-resistant Pseudomonas aeruginosa. Infection Control and Hospital Epidemiology 2007; 28: 1175–1180.
23.Van Delden, C. Pseudomonas aeruginosa bloodstream infections: how should we treat them? International Journal of Antimicrobial Agents 2007; 30: 71–75.
24.El Amari, EB, et al. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clinical Infectious Diseases 2001; 33: 1859–1864.
25.Colom, K, et al. Emergence of resistance to beta-lactam agents in Pseudomonas aeruginosa with group I beta-lactamases in Spain. European Journal of Clinical Microbiology and Infectious Diseases 1995; 14: 964–971.
26.Livermore, DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clinical Infectious Diseases 2002; 34: 634–640.
27.Paterson, DL. Looking for risk factors for the acquisition of antibiotic resistance: a 21st-century approach. Clinical Infectious Diseases 2002; 34: 1564–1567.
28.Raymond, DP, et al. Impact of antibiotic-resistant Gram-negative bacilli infections on outcome in hospitalized patients. Critical Care Medicine 2003; 31: 1035–1041.
29.Tejada Artigas, A, et al. Risk factors for nosocomial pneumonia in critically ill trauma patients. Critical Care Medicine 2001; 29: 304–309.
30.Cheong, HS, et al. Clinical significance and predictors of community-onset Pseudomonas aeruginosa bacteremia. American Journal of Medicine 2008; 121: 709–714.
31.Wisplinghoff, H, et al. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clinical Infectious Diseases 2003; 36: 1103–1110.
32.Tumbarello, M, et al. Factors associated with mortality in bacteremic patients with hematologic malignancies. Diagnostic Microbiology and Infectious Diseases 2009; 64: 320–326.
33.Wenzel, RP. Treating sepsis. New England Journal of Medicine 2002; 347: 966–967.
34.Cheong, HS, et al. Inappropriate initial antimicrobial therapy as a risk factor for mortality in patients with community-onset Pseudomonas aeruginosa bacteraemia. European Journal of Clinical Microbiology and Infectious Diseases 2008; 27: 1219–1225.
35.Micek, ST, et al. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrobial Agents and Chemotherapy 2005; 49: 1306–1311.
36.Tam, VH, et al. Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrobial Agents and Chemotherapy 2010; 54: 3717–3722.
37.Wu, YJ, Lin, SW, Chang, AC.48th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 25–28 October 2008. Abstract, K-3500.
38.Kang, CI, et al. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Microbial Drug Resistance 2005; 11: 68–74.
39.Blot, S, et al. Nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in critically ill patients: clinical outcome and length of hospitalization. Clinical Infectious Diseases 2002; 34: 1600–1606.